Vivos Inc (RDGL)

[chereb19]

Facts

"In our patent application (No.1811.191), we have developed a novel composition comprising yttrium-90 phosphate particles, which are specifically engineered for targeted therapeutic applications in the field of precision radiopharmaceutical therapy. These proprietary particles exhibit unique properties that make them ideal for use in products like Isopet® and Radiogel™, offering precise and effective delivery of therapeutic doses of radiation to targeted areas within the body. Our innovative yttrium-90 phosphate particles have been rigorously tested and found to demonstrate exceptional stability, biocompatibility, and therapeutic efficacy, making them a promising solution for the treatment of various medical conditions. With the issuance of this patent, we have established a solid foundation for extending patent protection for our proprietary particles, ensuring exclusivity in the production and utilization of these groundbreaking technologies for years to come."